ChatGPT Practices: Finance and Banking Domain
Journal of Business, Communication & Technology · 2024
DOI: 10.56632/bct.2024.3203 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Business, Communication & Technology, 2024. Verfasst von Md Khalid Hassan und 2 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
This paper reviews the practice of ChatGPT in the field of finance and banking through a natural language processing (NLP) system developed by OpenAI. We also discuss applications of ChatGPT in finance and banking, such as the detection of fraud, risk management, forecasting and analysis of the market, management of investments, chatbots for customer service, personal financial management, impact investing, and asset management along with its challenges, limitations and extremely encouraging future potentials. We also recommend taking necessary steps by the authorities to create and enhance ChatGPT-related legislation and regulations to avoid illegal and criminal offences. The paper concludes that ChatGPT will perform better and offer a better user experience for a variety of banking and finance sectors. It is worth remembering that in a relatively short period of time, ChatGPT has garnered significant attention from research, industry, and academia. This study will be helpful for policy makers, practitioners, and researchers.
Zitieren
APA
Hassan, M. K., Parvin, S., & Siddikee, J. A. (2024). ChatGPT Practices: Finance and Banking Domain. Journal of Business, Communication & Technology. https://doi.org/10.56632/bct.2024.3203
Vancouver
Hassan MK, Parvin S, Siddikee JA. ChatGPT Practices: Finance and Banking Domain. Journal of Business, Communication & Technology. 2024. doi:10.56632/bct.2024.3203
BibTeX
@article{Hassan2024,
author = {Hassan, Md Khalid and Parvin, Shahnaz and Siddikee, Jahangir Alam},
title = {ChatGPT Practices: Finance and Banking Domain},
journal = {Journal of Business, Communication & Technology},
year = {2024},
doi = {10.56632/bct.2024.3203}
}
EUVIMED